Overview
TBPH market data
Price History
TBPH price chart
Valuation & Profitability
- P/E (TTM)
- 7.64 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.25 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $10.82 – $21.03 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $875.4 · P/B 3.20 · P/S 7.97.
Company News
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026Globenewswire Inc · Jul 16, 2026, 11:00 AM
HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17Benzinga · Jul 7, 2026, 11:50 AM
Jones Trading Downgrades Theravance Biopharma to HoldBenzinga · Jun 29, 2026, 3:45 PM
BTIG Downgrades Theravance Biopharma to NeutralBenzinga · Jun 29, 2026, 3:35 PM
Zymeworks Targets Long-Term Cash Generation Through Theravance AcquisitionBenzinga · Jun 29, 2026, 1:25 PM
Zymeworks to Acquire Theravance Biopharma, Inc.Globenewswire Inc · Jun 29, 2026, 11:00 AM
8-K filing — Theravance Biopharma, Inc. (TBPH)SEC EDGAR · Jun 29, 2026, 10:30 AM